Rekombinanter Faktor VIIa bei Patienten mit Plättchenfunktionsstörungen oder Thrombozytopenien

Zusammenfassung

Rekombinanter Faktor VIIa (rFVIIa) wird über die zugelassenen Indikationen hinaus zunehmend zur Behandlung lebensbedrohlicher Blutungsereignissen bei Versagen der jeweiligen Standardtherapien eingesetzt. Kasuistiken und Fallserien dokumentieren die Wirksamkeit und Sicherheit von rFVIIa zur Blutstillung bei Patienten mit Thrombozytopathien und Thrombozytopenien verschiedener Ursache. Eine Zulassung zur Anwendung von rFVIIa liegt bei Patienten mit Thrombasthenie Glanzmann im Falle eines Refraktärzustandes auf die Transfusion von Thrombozytenkonzentraten vor. rFVIIa-Bolusapplikationen mit Dosierungen zwischen 80 und 120 μg/kg Körpergewicht alle 1,5 bis 3 Stunden werden auch bei Bernard-Soulier-Syndrom, Plättchen- Storage-Pool-Defekten und verschiedenen erworbenen Thrombozytopathien erfolgreich eingesetzt. Bei Thrombasthenie Glanzmann sind zur Gewährleistung einer effektiven Hämostase mindestens drei Bolusgaben notwendig. Bei Thrombozytopenie hat sich bei annähernd der Hälfte der Patienten ein einzelner rFVIIa-Bolus zur Beherrschung sonst unstillbarer Blutungen als ausreichend erwiesen. Dabei kann eine Blutstillung unter rFVIIa auch bei Thrombozytenwerten unter 20 000/μl erreicht werden, wenngleich bei höheren Thrombozytenkonzentrationen eine bessere Wirksamkeit erzielbar ist.

Summary

Apart from on-label indications, recombinant factor VIIa (rFVIIa) is increasingly administered for treatment of life threatening bleeding events when appropriate standard therapy fails. Case reports and short treatment series document the efficacy and safety of rFVIIa to achieve haemostasis in patients with platelet function disorders and thrombocytopenias of various origin. An established on-label indication for the use of rFVIIa is given in patients with Glanzmann thrombasthenia with refractoriness to transfusions of platelet concentrates. Bolus applications of rFVIIa at dosages between 80 and 120 μg/kg body weight every 1.5 to 3 h are also administered successfully in patients with Bernard-Soulier syndrome, platelet storage pool defects, and other acquired platelet function disorders. In patients with Glanzmann thrombasthenia, at least three bolus injections are required to achieve effective haemostasis. In approximately half of the patients with thrombocytopenias, a single bolus of rFVIIa has been shown to be sufficient in managing otherwise untreatable bleeding complications. In these patients, haemostasis was achieved even at platelet counts <20 000/μl, although the efficacy of rFVIIa increases at higher platelet concentrations.

Schlüsselwörter

Rekombinanter Faktor VIIa - Blutung - Thrombozytopathie - Thrombozytopenie - Hämostase

Keywords

Recombinant factor VIIa - bleeding - thrombocytopathy - thrombocytopenia - haemostasis

• Literatur

• 1 Almeida AM, Khair K, Hann I. et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-481.
• 2 Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
• 3 Ancliff P, Liesner R, Khair K. et al. The use of recombinant factor VIIa in a patient with severe Glanzmann’s thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagul Fibrinolysis 1999; 10: 447-448.
• 4 Altman R, Scazziota A, De Lourdes Herrera M. et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 4: 2022-2027.
• 5 Barnes C, Blanchette V, Canning P. et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005; 15: 145-150.
• 6 Baxter MS, Schroeder WS, Cheng Y. et al. Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Ann Pharmacother 2006; 40: 2053-2058.
• 7 Bay A, Oner AF. Glanzmann thrombasthenia successfully operated for nasal deformation with recombinant factor VIIA. Indian Pediatr 2006; 43: 1094.
• 8 Bell JA, Savidge GF. Glanzmann’s thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost 2003; 9: 167-170.
• 9 Brenner B, Hoffman R, Balashov D. et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005; 11: 401-410.
• 10 Busani S, Marietta M, Pasetto A. et al. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005; 93: 381-382.
• 11 Caglar K, Cetinkaya A, Aytac S. et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-438.
• 12 Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann Thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82: 1778.
• 13 Chuansumrit A, Suwannuraks M, Sri-Udomporn N. et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187-190.
• 14 Cervera JS, Mena-Duran AV, Piqueras CS. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost 2005; 93: 383-384.
• 15 Conesa V, Navarro-Ruiz A, Borras-Blasco J. et al. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int J Hematol 2005; 81: 75-76.
• 16 Coppola A, Simone CD, Palmieri NM. et al. Recombinant activated factor VII for hemostatic cover of orthopaedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagul Fibrinolysis 2007; 18: 199-201.
• 17 Coppola A, Tufano A, Cimino E. et al. Recombinant factor VIIa in a patient with Glanzmann´s thrombasthenia undergoing gynaecological surgery open issue in light of successful treatment. Thromb Haemost 2004; 92: 1450-1452.
• 18 Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 909-910.
• 19 Culligan DJ, Salamat A, Tait J. et al. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplantation 2003; 31: 1183-1184.
• 20 D’Oiron R, Ménart C, Trzeciak MC. et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-647.
• 21 Dargaud Y, Bordet JC, Trzeciak MC. et al. A case of Glanzmann’s thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91: 17-20.
• 22 De Fabritiis P, Dentamaro T, Picardi A. et al. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243-245.
• 23 Del Pozo Pozo AI, Jimenez-Yuste V, Villar A. et al. Successful thyroidectomy in a patient with Hermansky- Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis. 2002; 13: 551-553.
• 24 Devecioglu O, Unuvar A, Anak S. et al. Pyelithotomy in a patient with Glanzmann Thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turkish J Ped 2003; 45: 64-66.
• 25 Dominguez TE, Mitchell M, Friess SH. et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005; 6: 348-351.
• 26 Dempfle CE, Gulba D, Kirchmaier CM. et al. Klinische Bewertung potentieller Einsatzbereiche von rekombinantem Faktor VIIa bei internistischen und pädiatrischen Erkrankungen. Med Klin 2007; 102: 70-81.
• 27 Eller P, Pechlaner C, Wiedermann CJ. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding. Thromb J 2006; 4: 1477-1495.
• 28 Franchini M. The use of recombinant activated factor VII in life-threatening postpartum hemorrhage. Transfusion Alternatives in Transfusion Medicine 2007; 9: 1-7.
• 29 Gabriel DA, Li X, Monroe DM. et al. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2: 1816-1822.
• 30 Galan AM, Tonda R, Pino M. et al. Increased local procoagulant action: a mechanism contributing to the favourable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43: 885-892.
• 31 George JN, Colman RW. Overview of platelet structure and function. In: Colman et al (eds). Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams and Wilkins,; 2006: 437-442.
• 32 Gerhardt A, Scharf RE, Zotz RB. The use of recombinant factor VIIa (NovoSeven®) in a patient with Bernard Soulier syndrome and dental extraction. Blood 2006; 108: 67B.
• 33 Gerotziafas GT, Chakroun T, Depasse F. et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977-985.
• 34 Gerotziafas GT, Zervas C, Gavrielidis G. et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and lifethreatening hemorrhage. Am J Hematol 2002; 69: 219-222.
• 35 Gunaydin B, Ozkose Z, Pezek S. Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann’s thrombasthenia for nasal polipectomy. J Anesth 2007; 21: 106-107.
• 36 Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005; 16: 287-290.
• 37 Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-978.
• 38 Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
• 39 Hoffman R, Eliakim R, Zuckerman T. et al. Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukaemia. J Thromb Haemost 2003; 1: 606-608.
• 40 Inagaki M, Mori T, Tsunematsu Y. et al. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report. Blood Coagul Fibrinolysis 2006; 17: 317-322.
• 41 Kale A, Bayhan G, Yalinkaya A. et al. The use of recombinant factor VIla in a primigravida with Glanzmann’s thrombasthenia during delivery. J Perinat Med 2004; 32: 456-458.
• 42 Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004; 125: 95-96.
• 43 Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (NovoSeven®) on thrombocytopenia- like conditions in vitro. Semin Hematol 2001; 38 (Suppl. 12) 15-20.
• 44 Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5: 774-780.
• 45 Kristensen J, Killander A, Hippe E. et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 Suppl1 159-164.
• 46 Kurekci AE, Atay AA, Okutan V. et al. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005; 16: 145-147.
• 47 Langendonck L, Appel IM. Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease. Pediatr Blood Cancer 2005; 44: 676-678.
• 48 Lisman T, Moschatsis S, Adelmeijer J. et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-1870.
• 49 Lisman T, Adelmeijer J, Heijnen HF. et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3- deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-1727.
• 50 Lisman T, Adelmeijer J, Cauwenberghs S. et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3: 742-751.
• 51 Loertzer H, Soukup J, Fornara P. Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation--a retrospective analysis. Urol Int 2007; 78: 135-139.
• 52 Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann’s thrombasthenia. ClinAppl Thromb Hemost 2006; 12: 115-116.
• 53 Lopez-Vilchez I, Escolar G, Diaz-Ricart M. et al. Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost 2007; 97: 202-211.
• 54 Meijer K, Sieders E, Sloof MJH. et al. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998; 80: 204-205.
• 55 Millar CG, Stringer MD, Sugarman I. et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171-174.
• 56 Moisescu E, Ardelean L, Simion I. et al. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000; 11: 575-577.
• 57 Monroe DM, Hoffman M, Allen GA. et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-377.
• 58 Monte S, Lyons G. Peripartum management of a patient with Glanzmann´s thrombasthenia using Thrombelastograph®. Br J Anaesthesia 2001; 87: 734-738.
• 59 Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82: 257-258.
• 60 Nieswandt B, Watson SP. Platelet-collagen interaction: is GP VI the central receptor?. Blood 2003; 102: 449-461.
• 61 Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatology 2002; 22: 672-674.
• 62 Osborne W, Bhandari S, Tait RC. et al. Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol 2004; 26: 229-231.
• 63 Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005; 84: 816-822.
• 64 Pastores SM, Papadopoulos E, Voigt L. et al. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124: 2400-2403.
• 65 Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier Syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
• 66 Phelan 2nd JT, Broder J, Kouides PA. Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: a case report of bilateral uterine artery embolization. Am J Hematol 2004; 77: 151-155.
• 67 Pihusch M, Bacigalupo A, Szer J. et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-1944.
• 68 Poon M-C, Demers C, Jobin F. et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3953.
• 69 Poon MC, D’Oiron R, von Depka M. et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-1103.
• 70 Poon MC, Zotz R, Di Minno G. et al. Glanzmann’s thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43 (Suppl. 01) S33-S36.
• 71 Revesz T, Arets B, Bierings M. et al. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 355.
• 72 Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-178.
• 73 Scharf RE. Arterielle Thrombose. In: Ostendorf PC, Scharf RE, Aumiller J. et al. Thrombose Hämatologie-Onkologie. Ostendorf PC, Seeber S. (Hrsg). München: Urban-Schwarzenberg; 1997: 389-408.
• 74 Scharf RE, Clemetson KJ. Bernard-Soulier-Syndrom. In: Müller-Berghaus G, Pötzsch B. (Hrsg). Hämostaseologie. Molekulare und zelluläre Me- chanismen, Pathophysiologie und Klinik. Heidelberg: Springer; 1998: 53-56.
• 75 Scharf RE. Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Hämostaseologie 1996; 16: 114-138.
• 76 Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006; 81: 218-219.
• 77 Stepinska J, Banaszewski M, Konopka A. et al. Activated recombinant factor VII in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 2002; 87: 355-356.
• 78 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 971-982.
• 79 Tonda R, Galan AM, Mazzara R. et al. Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia. Semin Hematol 2004; 41 (Suppl. 01) 157-162.
• 80 Uzunlar HI, Eroglu A, Senel AC. et al. A patient with Glanzmann’s thrombasthenia for emergent abdominal surgery. Anesth Analg 2004; 99: 1258-1260.
• 81 Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. J Pediatr Hematol Oncol 2006; 28: 653-658.
• 82 Van Buuren HR, Wilenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann’s thrombasthenia. Dig Dis Sci 2002; 47: 2134-2136.
• 83 Vidarsson B, Onundarson P. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634-635.
• 84 Virchis A, Hughes C, Berney S. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah’s Witness with refractory immune thrombocytopenia. Hematol J 2004; 5: 281-282.
• 85 Von Heymann C, Schoenfeld H, Sander M. et al. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?. Heart Surg Forum 2005; 8: E39-E41.
• 86 Von Heymann C, Spies C, Grubitzsch H. et al. Blutungen nach herzchirurgischen Operationen. Die Rolle des rekombinanten Faktors VIIa. Hämostaseologie 2006; 26 (Suppl. 01) S77-S87.
• 87 Waddington DP, McAuley FT, Hanley JP. et al. The use of recombinant factor viia in a jehovah’s witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119: 286-288.
• 88 Walsh PN. Role of platelets in blood coagulation. In: Colman RW. et al (eds). Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams and Wilkins; 2006: 605-616.
• 89 Westrup D, Bassus S, Kirchmaier C. et al. Ultrastructure of a platelet clot from a thrombasthenia patient with no GPIIb/IIIa receptors and the influence of rFVIIa substitution. Platelets 2002; 13: 487-491.
• 90 White GC. Congenital and acquired platelet disorders: current dilemmas and treatment strategies. Semin Hematol 2006; 43 (Suppl. 01) S37-S41.
• 91 Wiesenack C, Arlt M, Liebold A. et al. Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2004; 128: 941-943.
• 92 Wilbourn B, Harrison P, Mackie IJ. et al. Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. Br J Haematol 2003; 122: 651-661.
• 93 Wrobel G, Dobaczewski G, Patkowski D. et al. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006; 47 Suppl 729-730.
• 94 Yilmaz BT, Alioglu B, Ozyurek E. et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005; 26: 843-845.
• 95 Zulfikar B, Kayran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15: 261-263.
• 96 Hacihanefioglu A, Tarkun P, Gonullu E. Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier-syndrome. Thromb Res 2007; 120: 455-457.